Scalable and efficient AAV production process with new Fibro chromatography technology

Production methods for adenovirus-associated virus (AAV) vectors have not kept up with the brisk pace of gene therapy development. To manufacture safe and efficacious clinical-grade virus, scalable and cost-effective production processes are needed. Towards this end, we present an efficient process for AAV production and scale-up in suspension cell culture through to purified bulk product. The process was developed by evaluating and optimizing each process step.

A novel fiber technology, Fibro, addresses the downstream bottleneck at the capture step by overcoming the diffusional and flow limitations of purification using packed-bed chromatography. Also, a new analytical assay based on surface plasmon resonance was developed for AAV quantitation.

In this webinar our panel of experts will discuss:

• How to optimize each process step of AAV production and scale-up in suspension cell culture.
• How to evaluate and optimize cell culture conditions and plasmid transfection.
• Purification methods based on filtration and chromatography, developed for AAV production.
• The advantages of Fibro chromatography in downstream processing of AAV.

Laura Adamson-Small

Upstream & Analytical Development Lead, AAV Process Development at UCB Pharma

Laura Adamson-Small has held multiple roles focused on improving AAV product quality and productivity through optimizing to viral gene expression, delivery, and upstream process design. She currently leads Upstream and Analytical Process Development for AAV vectors at UCB Biosciences in their Early Solutions team. She started her career in AAV supporting multiple aspects of AAV development at the University of Florida Powell Gene Therapy Center. Prior to joining UCB, she previously held led a team focusing on upstream process development and packaging plasmid design improvements for AAV vectors at Homology Medicines.

Mats Lundgren

Customer Applications Director at Cytiva

Mats has more than 25 years of experience in the field of biotechnology. He holds a PhD in Immunology, Cell and Molecular Biology from the Karolinska Institute, Stockholm, Sweden and extensive post-doc training at the MRC Clinical Sciences Centre, Imperial College School of Medicine in London, UK. In his industrial career Mats has had positions as scientist, team manager and Vice President at Pharmacia, AstraZeneca and smaller biotech companies.  In his previous function, Mats was managing both the Cell line and Upstream Process Development teams at a major biotech company.  In his current role, Mats works across different viral vector and vaccine application projects as well as general upstream topics, focusing on customer support, applicability of new technologies and manufacturing solutions.

Peter Guterstam

Product Manager, Advanced Therapeutics Downstream Solutions at Cytiva

Peter is Global Product Manager at Cytiva with responsibility for products tailored for downstream processing of Advanced Therapy Medicinal Products. He is based in Uppsala, Sweden. Peter earned is PhD in Neurochemistry from Stockholm University in 2009. He has been with GE since 2003, primarily working in various roles associated with oligonucleotide synthesis and purification. Since GE’s acquisition of Puridify, Peter has the business responsibility to develop products based on the Fibro technology to complement Cytiva’s portfolio of chromatography resins and to develop it further to generate tailored solutions for the manufacture of Advanced Therapy Medicinal Products.

Watch now

SPEAKERS

Laura Adamson-Small

Upstream & Analytical Development Lead, AAV Process Development at UCB Pharma

Mats Lundgren

Customer Applications Director at Cytiva

Peter Guterstam

Product Manager, Advanced Therapeutics Downstream Solutions at Cytiva

You might also like

Process in the product: a new analytical tool for AAV production optimization and monitoring

Blaž Bakalar, Ivana Petrović Koshmak

19 November

Watch

Innovative approaches to lentiviral vector purification: achieving high yields and purity with a chromatography-free process

Nikki Votaw

20 August

Watch

Accelerating AAV production: optimizing compound identification and process parameters

Keara Sutherland, Jean-Marc Guedon

20 November

Watch

Accelerating AAV process development with PAT-driven TFF system

Teva Smith

6 March

Watch

Increasing efficiency in AAV-based gene therapy production: platform optimization with multiserotype AAV affinity capture

Nicolas Laroudie, Tiago Albano

27 March

Watch